<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732364</url>
  </required_header>
  <id_info>
    <org_study_id>peter SECI</org_study_id>
    <nct_id>NCT04732364</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Ultrasound Guided Erector Spinae Block for Modified Radical Mastectomy</brief_title>
  <official_title>Analgesic Efficacy of Magnesium Sulphate as an Adjuvant to Levo-bupivacine in Ultrasound Guided Erector Spinae Plan Block for Modified Radical Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the analgesic efficacy of dexmedetomidine and magnesium sulphate as adjuvants to&#xD;
      levobupivacaine in erector spinae plane block in modified radical mastectomy surgery for&#xD;
      acute and chronic pain management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3 groups.&#xD;
&#xD;
      Group (C) / (I):20 patient (control group) :&#xD;
&#xD;
      Patients will receive 20 ml 0.25% levobupivacaine into the interfascial plane below erector&#xD;
      spinae muscle at level of T5.&#xD;
&#xD;
      Group (D)/ (II) :20 patient (Dexmetonidine group) :&#xD;
&#xD;
      Patient will receive 20ml 0.25% levobupivacaineas above + 1μ/kg dexmedetomidine.&#xD;
&#xD;
      Group (M) / (III) : 20 patient (magnesium slphate group) :&#xD;
&#xD;
      Patient will receive 20ml 0.25% levobupivacaineas above + 0.7 mg/kg MgSo4 . The patient, the&#xD;
      anesthesiologist who administered the drugs, and the data collector will be blinded to the&#xD;
      study drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analgesia requirement</measure>
    <time_frame>24 hours</time_frame>
    <description>first request for analgesia and total analgesia requirements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chronic pain assessment</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of chronic pain at 1-3 and 6 month post-operatively using LANSS pain score. a score of 12 or more is suggestive of neuropathic pain.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group (C) (control group):</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will receive 20 ml 0.25% levobupivacaine into interfascial plane below erector spinae muscle at level of T5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (D) (Dexmetonidine group):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 20ml 0.25% levobupivacaine + 1μ/kg dexmedetomidine into interfascial plane below erector spinae muscle at level of T5..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group (M) (magnesium slphate group):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive 20ml 0.25% levobupivacaine + 0.7 mg/kg MgSo4 into interfascial plane below erector spinae muscle at level of T5..</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound guided erector spinae plan block using bupivacaine for modified radical mastectomy</intervention_name>
    <description>Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle</description>
    <arm_group_label>Group (C) (control group):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound guided erector spinae plan block with bupivacaine and Dexmetonidine for modified radical mastectomy</intervention_name>
    <description>Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle</description>
    <arm_group_label>Group (D) (Dexmetonidine group):</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound guided erector spinae plan block with bupivacaine and magnesium slphate for modified radical mastectomy</intervention_name>
    <description>Ultrasound guided Erector spinae plane (ESP) block will be given with patient in sitting position depending on surgical site (left or right) ESP block will be given using high frequency linear u/s transducer, the probe is placed in longitudinal orientation lateral to thoracic fifth spinous process, then Trapezius muscle, Rhomboidus major muscle, and erector spinae muscle</description>
    <arm_group_label>Group (M) (magnesium slphate group):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female patient&#xD;
&#xD;
          -  American society of anesthesiologists (ASA) I and II physical status&#xD;
&#xD;
          -  age from 25 to 70 years old&#xD;
&#xD;
          -  scheduled for either left or right modified radical mastectomy (MRM).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  infection of the skin at or near site of needle puncture&#xD;
&#xD;
          -  coagulopathy&#xD;
&#xD;
          -  drug hypersensitivity or allergy to the studied drugs&#xD;
&#xD;
          -  central or peripheral neuropathy&#xD;
&#xD;
          -  significant organ dysfunction cardiac dysrrhythmias&#xD;
&#xD;
          -  obesity (BMI&gt;35kg/m2)&#xD;
&#xD;
          -  recently use analgesic drugs&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>peter R Edward, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>specialist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Egypt Cancer Institute</name>
      <address>
        <city>Assiut</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Peter Rafaat Edward Iskander</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Erector Spinae Block</keyword>
  <keyword>magnesium sulphate</keyword>
  <keyword>dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

